167 related articles for article (PubMed ID: 38433190)
1. EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy.
Wang Z; He Z; Wan J; Chen A; Cheng P; Zhu W
J Nanobiotechnology; 2024 Mar; 22(1):89. PubMed ID: 38433190
[TBL] [Abstract][Full Text] [Related]
2. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
[TBL] [Abstract][Full Text] [Related]
3. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.
Posthumadeboer J; Piersma SR; Pham TV; van Egmond PW; Knol JC; Cleton-Jansen AM; van Geer MA; van Beusechem VW; Kaspers GJ; van Royen BJ; Jiménez CR; Helder MN
Br J Cancer; 2013 Oct; 109(8):2142-54. PubMed ID: 24064975
[TBL] [Abstract][Full Text] [Related]
4. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
[TBL] [Abstract][Full Text] [Related]
5. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
6. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma.
Ray S; Saha S; Sa B; Chakraborty J
Drug Deliv Transl Res; 2017 Apr; 7(2):259-275. PubMed ID: 28050892
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.
Lee DH; Thoennissen NH; Goff C; Iwanski GB; Forscher C; Doan NB; Said JW; Koeffler HP
Cancer Lett; 2011 Jul; 306(2):161-170. PubMed ID: 21440986
[TBL] [Abstract][Full Text] [Related]
9. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells.
Bazavar M; Fazli J; Valizadeh A; Ma B; Mohammadi E; Asemi Z; Alemi F; Maleki M; Xing S; Yousefi B
Pathol Res Pract; 2020 Nov; 216(11):153176. PubMed ID: 32861171
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
11. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
12. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-F127 conjugated mesoporous zinc hydroxyapatite as an efficient drug delivery system for overcoming chemotherapy resistance in osteosarcoma cells.
Meshkini A; Oveisi H
Colloids Surf B Biointerfaces; 2017 Oct; 158():319-330. PubMed ID: 28711857
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature.
Patil MA; Upadhyay AK; Hernandez-Lagunas L; Good R; Carpenter TC; Sucharov CC; Nozik-Grayck E; Kompella UB
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1059-S1066. PubMed ID: 30450979
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
16. Polydopamine-modified ZIF-8 nanoparticles as a drug carrier for combined chemo-photothermal osteosarcoma therapy.
Yin X; Ran S; Cheng H; Zhang M; Sun W; Wan Y; Shao C; Zhu Z
Colloids Surf B Biointerfaces; 2022 Aug; 216():112507. PubMed ID: 35523102
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
Scionti I; Michelacci F; Pasello M; Hattinger CM; Alberghini M; Manara MC; Bacci G; Ferrari S; Scotlandi K; Picci P; Serra M
Ann Oncol; 2008 Aug; 19(8):1500-1508. PubMed ID: 18385200
[TBL] [Abstract][Full Text] [Related]
18. Homing peptide-conjugated gold nanorods: the effect of amino acid sequence display on nanorod uptake and cellular proliferation.
Alkilany AM; Boulos SP; Lohse SE; Thompson LB; Murphy CJ
Bioconjug Chem; 2014 Jun; 25(6):1162-71. PubMed ID: 24892190
[TBL] [Abstract][Full Text] [Related]
19. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.
Xu W; Li Z; Zhu X; Xu R; Xu Y
Med Sci Monit; 2018 Dec; 24():8812-8821. PubMed ID: 30518744
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
